Risk-off into the inflation print. Monday’s chip-led bounce faded fast — Tuesday’s renewed AI selloff knocked the Nasdaq down hard (FT flagged a ~3% drop) — and this morning US futures are soft, gold has slumped below $4,200 and Bitcoin is in its worst week since the FTX crash, all ahead of US May CPI (14:30 Rome), seen at a hot +4.2% headline. Rates are skewing hawkish (bond positioning flags Fed hikes; BOJ tipped for two 2026 hikes from next week). Yet the AI capital machine roars on: ASML is now Europe’s most valuable company ever, SpaceX’s IPO is heavily oversubscribed, and Google is backstopping a $35bn private-credit chip deal for Anthropic. Overlay: the US struck Iran after a downed Apache, testing the April ceasefire.
Europe/Rome 06:00 · Trading week · tech selloff reignites · Risk tone: defensive into hot CPI
Levels below are the Bloomberg Europe “Top Securities” ticker read at ~06:00 Rome Wednesday. With US cash shut pre-open, the index prints are Tuesday’s closing levels — the session a renewed AI/tech selloff dragged lower (Nasdaq off sharply). The live move is the pre-CPI risk-off in round-the-clock markets (gold below $4,200, Bitcoin’s worst week since FTX) and a softer Asia. The week’s swing event is US May CPI today (14:30 Rome, ~+4.2% headline expected — would be the hottest since early 2023), with the FOMC (16–17 June) the marquee event into rising rate-hike chatter.
Top of the morning
US strikes Iran after an Apache is shot down — April ceasefire tested
Washington carried out strikes on Iran after one of its Apache helicopters was downed, with a surface naval drone used to rescue the crew. The episode lays bare how fragile the early-April ceasefire is and complicates nascent peace talks; both sides signal they can escalate. Markets read it through oil — crude carries a modest risk premium (~$89) and aluminium slipped to a one-month low — though prices have eased over the week. An ex-Australian envoy argues the US still needs a “strategic victory”; Italy extended a fuel-tax cut to blunt the domestic hit.
Stocks defensive before a hot CPI; the AI trade wobbles again
After Monday’s relief bounce, Tuesday brought a renewed tech selloff (FT: Nasdaq ~−3% intraday as AI-linked names led lower). This morning futures are soft and the old havens aren’t cushioning — gold slumped below $4,200 and Bitcoin had its worst week since FTX. The catalyst is US May CPI at 14:30 Rome, with consensus near +4.2% y/y headline (core ~2.9%) — a print that would harden “the Fed may have to hike” fears.
ASML becomes Europe’s most valuable company ever on the AI boom
The Dutch lithography monopolist hit a record high to top Europe’s market-cap table for the first time, even as Bloomberg notes its multiple still looks modest versus US chip peers — an argument the rally has further to run. CEO Christophe Fouquet, meanwhile, warned the EU against directing chip supplies, calling for “champions,” not intervention. A direct, bullish read on your semiconductor shelf.
AI capital machine roars on: SpaceX oversubscribed, $35bn Anthropic deal, OpenAI pipeline
Despite the equity wobble, the financing wave keeps building: SpaceX’s IPO drew orders for multiple times the shares on offer, Google is backstopping a $35bn private-credit chip deal (Apollo/Blackstone) to fund Anthropic, OpenAI sits in a $3.6tn AI IPO pipeline, and China is readying a ~$295bn nationwide AI buildout. FT’s flag: that supply wave could weigh on existing stocks by soaking up liquidity — even as another FT note argues earnings, not just valuations, are driving the market.
Rates turn hawkish; Japan’s long bond stumbles; private credit twitchy
Bond positioning now signals the Fed could hike soon, FT columnists warn the “punch bowl” may be pulled, and BOJ watchers see two 2026 hikes starting next week. Japan’s 30-year auction drew its weakest demand in a year and the 10-year US yield sits ~4.54%. Beneath the tape, private credit is both funding the AI boom and showing strain — retail investors are starting to eye the exits.
Xi–Kim summit reverberates; South China Sea friction flares
After a lavish welcome for Xi in Pyongyang, the US pushed back on any notion that North Korea’s nuclear arsenal is a “closed issue.” The Philippines pressed China to remove a structure on a disputed shoal and floated sea-border talks with Japan. Elsewhere: the UK threatened long prison terms after Iran-linked antisemitic attacks; Graham Platner won Maine’s Democratic Senate primary; a judge rejected Trump’s $100,000 H-1B visa fee; and Peru’s presidential vote remains too close to call.
Health watch: GSK’s cancer-deal spree, Boots up for sale, a pollution-and-heart study
Pharma M&A stays hot — GSK is pursuing a $10.6bn cancer deal and is in talks to buy biotech Nuvalent for >$9bn — while the Weston family and Australia’s Sigma negotiate a ~$10bn sale of Boots. A new Canadian study links urban air pollution to ongoing cardiovascular damage via CT imaging, and China’s healthcare stocks slid to record-low valuations as capital chases AI. A cannabis-based drug for back pain is also being pitched to displace opioids.
FT portfolio signal · tied to your holdings
What FT flagged for your book
Macro / regime read. The tone has flipped risk-off into today’s CPI, and the dashboard’s regime gauges are all flashing — though none at a severe trigger yet. Volatility is live (Tuesday’s ~3% Nasdaq drop; FT’s desk in full “volatility heaven” / “why are investors so jumpy” mode). Rates skew hawkish: FT (Bernstein) warns the Fed “might take the punch bowl away,” squaring with bond positioning for fast hikes and a hot +4.2% headline CPI — a direct headwind for high-multiple and rate-sensitive names. The notable tell is safe-haven failure: Unhedged calls gold and bitcoin “the assets the rally forgot,” and both are rolling over (gold <$4,200, BTC’s worst week since FTX) rather than cushioning the equity wobble. And an equity-supply overhang is building — FT warns the SpaceX/Anthropic/OpenAI IPO wave plus slowing buybacks could drain support from existing stocks. War-chest deployment rules stay dormant: this is a regime to respect, not deploy into.
Broadcom (shelf single-name — the standout). FT details the $35bn Apollo/Blackstone private-credit package financing Anthropic’s growth — a deal sitting squarely on Broadcom’s custom-silicon demand and Google’s backstop. Read it two ways: a strong AI-capex demand signal for a direct holding, and a marker of how much of the buildout now rides on private credit (a regime to watch, not yet a stress).
ASML (shelf — semis). Now Europe’s most valuable company ever, with Bloomberg arguing the valuation is still undemanding vs US peers; CEO Fouquet pushed back on EU plans to direct chip supplies. Unambiguously positive for the semi shelf — the cleanest single-name read today.
Microsoft (shelf — policy/tax). Two Microsoft-tagged alerts: Ireland told to rein in its corporate-tax windfall, and EU capitals set to gut a “sacrificial lamb” first-draft budget while debating cuts to US-tech reliance. Watch-items on the European tax/regulatory backdrop, not near-term catalysts.
Novo Nordisk & Eli Lilly (shelf — GLP-1). The standing watch-item: AstraZeneca is advancing an oral weight-loss pill aimed at the obesity leaders. Competitive-threat signal for both names; track the read-through to pricing and share as the oral-obesity race intensifies.
Caterpillar (shelf — AI capex). FT’s “picks and shovels” piece keeps Caterpillar among the once-staid industrials lifted by the data-centre scramble — the buildout flowing into the physical layer (gensets, earthmoving), a positive read on a direct holding.
Pharma M&A (theme — Vertex / Thermo Fisher corner). GSK’s cancer-deal wave (Nuvalent >$9bn; a $10.6bn deal) signals drugmakers paying up to refill pipelines — a supportive backdrop for the biotech-adjacent shelf. No direct Vertex/Thermo single-name alert in the window.
Shelf single-names live today:Broadcom (the $35bn Anthropic financing), ASML (Europe’s most-valuable record), Microsoft (EU tax/budget), Caterpillar (AI-capex), and the standing Novo Nordisk / Eli Lilly obesity watch. Pharma-M&A (GSK) and the AI-capex/IPO-supply theme round it out. (Name-level alerts surface here once FT routes them to this Gmail — see the iCloud→Gmail forwarding note if they stay sparse.)
Net: risk-off into a hot CPI, with gold and bitcoin failing to cushion and rates skewing hawkish — a two-sided, respect-don’t-deploy regime. But the AI capital machine (ASML record, SpaceX/Anthropic/OpenAI supply, Broadcom-financed buildout, Caterpillar picks-and-shovels) keeps the shelf’s structural thesis intact. Watch-item: AstraZeneca’s obesity pill vs Novo / Lilly. War-chest rules dormant — no severe trigger.
Markets snapshot
Bloomberg Europe “Top Securities” ticker, read ~06:00 Rome Wednesday. US cash is shut pre-open, so the index prints are Tuesday’s closing levels — the session a renewed AI selloff dragged lower. Round-the-clock markets (gold, crude, FX, crypto) are live pre-CPI reads; the move column compares to Monday’s close (the last briefing) where useful.
Instrument
Last
Move / context
S&P 500
7,386.65
−0.7% vs Mon · renewed tech selloff, soft pre-CPI
Nasdaq
25,678.82
−1.5% vs Mon · FT flagged ~3% AI-led drop Tue
Bloomberg 500
2,669.20
−0.7% vs Mon
FTSE 100
10,227.33
−1.4% Tue · broad risk-off
US 10-year Treasury
4.54%
yields firm · positioning signals Fed hikes
EUR/USD
~1.15
steady pre-CPI
GBP/USD
~1.34
a touch firmer
Crude Oil (WTI)
$88.86
+0.8% today · Iran premium; eased ~$2 on the week
Gold (spot)
$4,199.50
below $4,200 · ~−2% on Fed/rate bets (−3.8% from Mon)
Figures transcribed from the Bloomberg Europe “Top Securities” ticker. Pre-open Wednesday the US index prints remain Tuesday’s cash close — the renewed-selloff session (FT: Nasdaq ~−3% intraday). Gold, crude, FX and crypto trade round-the-clock and reflect the live pre-CPI risk-off (gold below $4,200; Bitcoin’s worst week since the FTX crash). US May CPI at 14:30 Rome is the next catalyst.
Global markets & macro
The week’s relief rally has reversed. After Monday’s chip-led bounce, Tuesday delivered a renewed AI/tech selloff — FT reported the Nasdaq off roughly 3% intraday as AI-linked names led lower — and this morning equities are defensive ahead of the main event: US May CPI at 14:30 Rome, with consensus near +4.2% y/y headline (core ~2.9%), which would be the hottest headline since early 2023. That print is colliding with a hawkish rates turn: bond positioning now signals the Fed could be forced to hike, FT columnists warn the “punch bowl” may be pulled, BOJ watchers see two 2026 hikes starting next week, and Japan’s 30-year auction just drew its weakest demand in a year. The 10-year sits ~4.54%. Tellingly, the old safe-havens aren’t cushioning the wobble — gold slumped below $4,200 and Bitcoin had its worst week since the FTX collapse, “the assets the rally forgot,” as FT’s Unhedged put it.
Yet the AI capital-formation machine is running flat out through the turbulence. ASML became Europe’s most valuable company ever; SpaceX’s IPO drew orders for multiple times the shares available; Google is backstopping a $35bn private-credit chip deal (Apollo/Blackstone) to finance Anthropic; OpenAI sits in a $3.6tn AI IPO pipeline; and China is readying a ~$295bn nationwide AI buildout. FT frames the paradox from both sides — the IPO-supply wave plus slowing buybacks could weigh on existing stocks by absorbing liquidity, even as a separate FT note argues it’s earnings, not stretched valuations, fuelling the market. Beneath it all, private credit is quietly funding the boom while showing the first signs of strain (retail starting to edge out). FX stayed quiet — the euro near 1.15, sterling around 1.34. The swing events are close: today’s CPI, then the path to the 16–17 June Fed.
Geopolitics & world news
The Middle East is back in the foreground. The US struck Iran after one of its Apache helicopters was shot down, using a surface naval drone to rescue the downed crew — an episode that underscores how fragile the early-April ceasefire is and tests fledgling peace talks. Markets read it through oil: crude carries a modest risk premium (~$89) and aluminium slipped to a one-month low on the tension, though prices have eased over the week. An ex-Australian envoy argues the US still needs a “strategic victory” in Iran; Italy extended a fuel-tax cut to 3 July to soften the war’s domestic impact; and Bloomberg notes Iran’s economy has, so far, proven harder to break than expected.
In Asia, the Xi–Kim summit reverberates: after a lavish welcome in Pyongyang, Washington pushed back on any sense that North Korea’s nuclear arsenal is a “closed issue,” while the Philippines pressed China over a disputed shoal and floated sea-border talks with Japan. Elsewhere: the UK threatened 14-year prison terms after Iran-linked antisemitic attacks and Starmer condemned a Belfast knife attack; in US politics, Graham Platner won Maine’s Democratic Senate primary, a judge rejected Trump’s $100,000 H-1B visa fee, and Peru’s presidential vote remains too close to call. The 2026 World Cup is getting under way. For the medical reader, Bloomberg flags US budget cuts costing community health workers their jobs — a thinning of the safety net in under-served areas — alongside the cannabis-for-back-pain pitch to displace opioids.
Clinical desk · NEJM current issue (4 June 2026)
This week in the New England Journal
A deeper read of the issue’s practice-relevant trials, with the numbers that matter at the bedside. (NEJM publishes weekly on Thursdays, so the 4 June issue is still current this Wednesday — the next issue lands tomorrow, 11 June. Carried forward unchanged from the same issue; no re-read needed.)
Cardiology — LAAC moves toward the anticoagulation-eligible
CHAMPION-AF randomised 3,000 AF patients who were suitable NOAC candidates (mean CHA₂DS₂-VASc 3.5) to a Watchman Flx device or a NOAC. At 3 years the composite of CV death, stroke or systemic embolism was 5.7% vs 4.8% (difference 0.9 pp, 95% CI −0.8 to 2.6) — meeting noninferiority — while non–procedure-related bleeding was roughly halved (10.9% vs 19.0%, HR 0.55), a superiority win. Caveats worth holding onto: strokes were numerically higher with the device (3.6% vs 2.5%; ischaemic stroke/systemic embolism ~0.3%/yr more), the highest-risk patients (CHA₂DS₂-VASc ≥5) were under-represented, only one device was studied, and the trial was industry-funded with an absolute (not relative) noninferiority margin. The companion editorial asks directly whether indications should now widen. Practical read: a stronger case for LAAC as a shared-decision option in bleeding-averse but anticoagulation-eligible AF — the 5-year stroke data will be the tell.
Critical care — high-flow oxygen: fewer intubations, same mortality
SOHO (42 French ICUs, 1,110 patients with P/F ≤200) found day-28 mortality identical at 14.6% vs 14.6% (P=0.98) for high-flow nasal oxygen vs standard oxygen. Intubation by day 28 was lower with high-flow (42.4% vs 48.4%, difference −5.9 pp), but serious events during spontaneous breathing (cardiac arrest or pneumothorax) were numerically more frequent (2.3% vs 1.1%). Read: this tempers the mortality rationale for HFNC; the intubation benefit persists, so the case stays individualised rather than universal.
Oncology — a step-change in pancreatic cancer
Daraxonrasib (RASolute 302). Phase 3, 500 patients with previously treated metastatic PDAC (92% RAS G12); this oral RAS(ON) inhibitor roughly doubled median overall survival vs chemotherapy (13.2 vs 6.6 months, HR 0.40, P<0.001) and improved PFS (7.3 vs 3.5 months, HR 0.45). Grade ≥3 events were actually lower than chemo (61.8% vs 69.6%) and treatment-related discontinuations far lower (1.2% vs 11.2%). In a disease where median survival is under a year, this is the standout result of the issue.
Perioperative apalutamide (PROTEUS). Phase 3, 2,109 patients, ADT ± apalutamide around radical prostatectomy. Pathological complete response / minimal residual disease rose to 8.9% vs 1.0% (OR 10.2) and 5-year metastasis-free survival to 78.2% vs 73.5% (HR 0.80, P=0.02); grade 3/4 events were higher (39.6% vs 31%, mostly rash). The first practice-changing neoadjuvant signal in prostate cancer — though the absolute MFS gain (~4.7 pp) is modest, and the editorial’s “watershed” framing is about direction more than magnitude.
Also: all-oral decitabine–cedazuridine + venetoclax gave complete responses in ~47% of newly diagnosed AML; adjuvant selpercatinib lengthened event-free survival in RET fusion–positive early-stage NSCLC.
AI in the clinic (your beat)
The governance layer is catching up to deployment. A Perspective on ambient AI documentation maps the recording-consent problem — two-party-consent states, where audio is transmitted, and the patchwork of state law that every ambient-scribe pilot now runs into — alongside an NEJM AI review on large language models in informed consent (opportunities vs thin evidence), a privacy analysis of AI scribes, and a behavioural-health letter warning that chatbot empathy can outpace accuracy. Collectively: useful tools, but consent, privacy and monitoring are the gating issues, not raw capability.
Infectious disease
A correspondence characterises the 2025 Sudan virus (an ebolavirus) outbreak in Uganda, and another reports that IV artesunate still performed acceptably in children with partially artemisinin-resistant severe malaria (PfK13 mutations) — reassuring that parenteral artesunate remains usable as a first-line parenteral agent.
Briefly noted
Obexelimab cut flares and glucocorticoid use in a phase-3 trial in IgG4-related disease; secukinumab hit its mark in relapsed polymyalgia rheumatica but missed in giant-cell arteritis; dual CAR T-cell desensitisation enabled kidney transplantation in two highly HLA-sensitised candidates; and a clinical-practice review distils what actually moves childhood vaccine hesitancy (clinician recommendation, presumptive framing, empathy).
Carried forward from the NEJM current issue (4 June 2026, still current today; next issue tomorrow, 11 June), originally read via Control Chrome on Luca’s subscription — CHAMPION-AF, SOHO, RASolute 302 and PROTEUS, plus the selpercatinib and all-oral-AML papers and the ambient-AI-consent pieces. Figures summarised in original prose under copyright caution — not reproductions, and not medical advice for any individual patient.
Today & week ahead (CET)
Wed 10US May CPI · 14:30 — headline seen ~+4.2% y/y (hottest since early 2023); the day’s main catalyst · gold <$4,200, BTC worst week since FTX · tech-selloff follow-through & Iran headlines
This wkSpaceX IPO pricing/allocation · OpenAI & Anthropic IPO pipeline · BOJ decision next week · FIFA World Cup 2026 under way
16–17FOMC — rate decision, projections, press conference; lands into rising rate-hike expectations (the marquee event on the horizon)
Jun 24Fed releases Wall Street bank stress-test results
WatchIran ceasefire durability (Apache-downing fallout) · CPI & rates read-through · private credit · AstraZeneca obesity pill vs Novo / Lilly · DR Congo / Ebola response